Genovis AB (publ.) (GENO)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 20.15 |
|---|---|
| 52-week range | 15.64 – 23.65 |
| Return, 1 month / 3 months | +0.7% / +3.5% |
| Return, 1 year / 3 years | −5.2% / −47.8% |
| Trend | Uptrend |
| RSI (14) | 53 |
| Volatility (1 year) | 40.2% |
| Worst drawdown (1 year) | -30.3% |
| Average daily value traded | 3.51M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Genovis AB is a Swedish life science company based in Lund that develops and supplies enzymes and reagents used in protein and antibody research. Its product range includes enzyme tools that help laboratories prepare, analyse and modify antibodies and other proteins. Customers are mainly pharmaceutical and biotechnology companies, contract research organisations and academic research laboratories that work with biopharmaceutical development and protein characterisation. The company also offers related services and products for laboratory workflows.
On this site Genovis AB (publ.) appears as a stock on the Stockholm Exchange (Sweden), code GENO, with prices in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Genovis AB (publ.) (GENO) trades on the Stockholm Exchange in Sweden. It last closed at SEK 20.15 on 19 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 235 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 5.2% and over the last three months it rose 3.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 70 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 3.2% | ||
| From 52-week high | -13.1% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 3.5% | ||
| 6-month return | 0.0% | ||
| 12-month return, skipping the last month | -5.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 40.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -30.3% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 3.51M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.4% |
|---|---|
| 1 month | +0.7% |
| 3 months | +3.5% |
| 6 months | +0.0% |
| 1 year | −5.2% |
| 3 years | −47.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 20.09 / 19.53 |
|---|---|
| Golden / death cross (60 days) | Golden, 36 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.84 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.